| Description | Brigimadlin (BI 907828) is an orally active and highly potent E3 ubiquitin-protein ligase MDM2-p53 antagonist with antitumor activity.Brigimadlin can be used to study metastatic BTC, PDAC, lung adenocarcinoma, or bladder cancer. |
| In vitro | Brigimadlin （0-10 nM；48 h）能 抑制 BT48, BT50, BT67, BT69, BT89, BT94的增殖，其IC50 分别为 58.5, 21.1, 37.9, 89.8, 16.7, 46.8 pM[1]. |
| Synonyms | BI 907828, BI907828, BI-907828 |
| molecular weight | 591.46 |
| Molecular formula | C31H25Cl2FN4O3 |
| CAS | 2095116-40-6 |
| Storage | keep away from direct sunlight,store at low temperature | store at -20°C |
| References | 1. Hao X, et al. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models. Neuro Oncol. 2023 May 4;25(5):913-926. 2. Yoo C, et al. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. Future Oncol. 2024 Jan 12. |